Adma Biologics Inc. (ADMA)
NASDAQ (NMS) NASDAQ (NMS) Primary 
ADMA Biologics: A Compelling GARP Stock For Biotech Investors
ADMA Biologics focuses on developing and commercializing plasma-derived products, primarily targeting immune-compromised patients. Revenue streams come from FDA-approved products, immunotechnology, and CDMO services, with a promising US immunoglobulin market. The company's IP portfolio includes three FDA-approved drugs: Asceniv, Bivigam, and Nabi-HB.
Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
What's in Store for ADMA Biologics (ADMA) in Q2 Earnings?
On ADMA Biologics' (ADMA) second-quarter 2024 earnings call, investors are likely to focus on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.
Adma Biologics (ADMA) Declines More Than Market: Some Information for Investors
Adma Biologics (ADMA) reachead $13.05 at the closing of the latest trading day, reflecting a -1.81% change compared to its last close.
Add These 5 Hot Biotech Stocks In July
Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you're investing in companies that are working to treat or heal medical ailments that cause issues for people around the world.
5 Stocks With Recent Price Strength to Tap Wall Street Rally
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are ADMA, AMSC, BTMD, LINC, CORT.
3 Millionaire-Making Stock Picks With Astounding Growth Potential
Finding millionaire-making stocks is not easy. While we can't tell the future, we can do the next best thing: think forward, gauge a company's room for growth, and determine how it intends to reach the next level.
Is ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Here is how Adma Biologics (ADMA) and Aclaris Therapeutics (ACRS) have performed compared to their sector so far this year.
Adma Biologics (ADMA) is on the Move, Here's Why the Trend Could be Sustainable
Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Adma Biologics (ADMA) Surpasses Market Returns: Some Facts Worth Knowing
Adma Biologics (ADMA) reachead $11.64 at the closing of the latest trading day, reflecting a +1.57% change compared to its last close.
Wall Street Bulls Look Optimistic About Adma Biologics (ADMA): Should You Buy?
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Adma Biologics (ADMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Adma Biologics (ADMA) concluded the recent trading session at $10.84, signifying a -1.54% move from its prior day's close.
